Rockefeller Capital Management
BIO icon

Rockefeller Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rockefeller Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
3,427
+1,659
+94% +$471K ﹤0.01% 1696
2026
Q1 		$493K Buy
1,768
+721
+69% +$208K ﹤0.01% 1984
2025
Q4 		$317K Sell
1,047
-501
-32% -$156K ﹤0.01% 2127
2025
Q3 		$434K Buy
+1,548
New +$421K ﹤0.01% 1835
2023
Q2 		– Sell
-534
Closed -$254K – 1829
2023
Q1 		$254K Sell
534
-125
-19% -$58.5K ﹤0.01% 1677
2022
Q4 		$276K Sell
659
-60
-8% -$24.2K ﹤0.01% 1513
2022
Q3 		$299K Buy
719
+124
+21% +$61.8K ﹤0.01% 1470
2022
Q2 		$294K Buy
595
+107
+22% +$55.7K ﹤0.01% 1475
2022
Q1 		$274K Sell
488
-1,119
-70% -$675K ﹤0.01% 1560
2021
Q4 		$1.21M Sell
1,607
-17
-1% -$12.7K 0.01% 983
2021
Q3 		$1.21M Sell
1,624
-106
-6% -$79.4K 0.01% 928
2021
Q2 		$1.11M Sell
1,730
-374
-18% -$228K 0.01% 889
2021
Q1 		$1.2M Buy
2,104
+16
+0.8% +$9.47K 0.01% 728
2020
Q4 		$1.22M Buy
2,088
+140
+7% +$79.7K 0.01% 641
2020
Q3 		$1M Buy
1,948
+285
+17% +$144K 0.01% 596
2020
Q2 		$751K Buy
1,663
+1,361
+451% +$601K 0.01% 600
2020
Q1 		$106K Buy
302
+91
+43% +$33.5K ﹤0.01% 998
2019
Q4 		$78K Buy
211
+5
+2% +$1.76K ﹤0.01% 1027
2019
Q3 		$69K Buy
206
+190
+1,188% +$62K ﹤0.01% 887
2019
Q2 		$5K Sell
16
-248
-94% -$74.3K ﹤0.01% 1416
2019
Q1 		$81K Buy
+264
New +$71.2K ﹤0.01% 804

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rockefeller Capital Management's BIO Position: Q2 2026 in Review

Rockefeller Capital Management increased its Bio-Rad Laboratories Class A (BIO) stake by 94% in Q2 2026, buying an estimated $471K and bringing the position to 3,427 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Rockefeller Capital Management first reported a position in BIO in Q1 2019 and has held it in 21 quarters since. The position peaked at $1.22M in Q4 2020. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Rockefeller Capital Management held 3,427 shares of Bio-Rad Laboratories Class A worth $1.01M as of Q2 2026.
  • Rockefeller Capital Management bought 1,659 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $471K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1696 holding.
  • Rockefeller Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and has held it in 21 quarters since.
  • Rockefeller Capital Management's Bio-Rad Laboratories Class A position peaked at $1.22M in Q4 2020.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.